19:54 , Jun 9, 2017 |  BC Week In Review  |  Company News

Threshold grants OBI ex-Asian rights to TH-3424

OBI Pharma Inc. (TPEx:4174) acquired ex-Asian development and commercialization rights to OBI-3424 (formerly TH-3424) from Threshold Pharmaceuticals Inc. (NASDAQ:THLD) for an undisclosed upfront payment. OBI receives rights worldwide, excluding Taiwan, Japan, South Korea, Singapore, Malaysia,...
21:09 , Dec 30, 2016 |  BC Week In Review  |  Company News

Threshold, NIH deal

Threshold and NIH’s NCI partnered to conduct preclinical testing assessing the biotech’s TH-3424 (AST-106) against T cell acute lymphoblastic leukemia (ALL) xenograft cell lines, which highly express aldo-keto reductase family 1 member C3 (AKR1C3). TH-3424...
18:32 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat NSCLC and squamous cell carcinoma of the head and neck (SCCHN) or skin...
18:26 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and...
08:00 , Feb 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Aldo-keto reductase family 1 member C3 (AKR1C3) In vitro studies identified specific AKR1C3 inhibitors that...
07:00 , Jul 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Polymerase (DNA...
07:00 , May 14, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various ...